REN and type 2 diabetes mellitus: Increasing evidence shows that the pathological stimulation of the renin–angiotensin system (RAS) is associated with type 2 diabetes and that RAS inhibitors, either Angiotensin (Ang) II type 1 receptor blockers (ARBs) or Angll-converting enzyme inhibitors (ACEi), delay new onset-type 2 diabetes in high-risk populations (Abuissa et al., 2005; Prisant 2004).